S&P 500   2,507.52 (-2.98%)
DOW   21,341.90 (-2.62%)
QQQ   186.19 (-2.22%)
AAPL   246.42 (-3.09%)
FB   161.92 (-2.93%)
MSFT   155.82 (-1.20%)
GOOGL   1,121.92 (-3.45%)
AMZN   1,929.24 (-1.05%)
CGC   14.11 (-2.49%)
NVDA   256.04 (-2.87%)
BABA   191.16 (-1.71%)
MU   41.44 (-1.47%)
GE   7.25 (-8.69%)
TSLA   504.79 (-3.67%)
AMD   46.20 (+1.58%)
T   28.13 (-3.50%)
ACB   0.85 (-6.59%)
F   4.54 (-6.00%)
NFLX   368.75 (-1.80%)
BAC   20.01 (-5.79%)
GILD   73.31 (-1.94%)
PRI   85.31 (-4.05%)
DIS   96.12 (-0.50%)
S&P 500   2,507.52 (-2.98%)
DOW   21,341.90 (-2.62%)
QQQ   186.19 (-2.22%)
AAPL   246.42 (-3.09%)
FB   161.92 (-2.93%)
MSFT   155.82 (-1.20%)
GOOGL   1,121.92 (-3.45%)
AMZN   1,929.24 (-1.05%)
CGC   14.11 (-2.49%)
NVDA   256.04 (-2.87%)
BABA   191.16 (-1.71%)
MU   41.44 (-1.47%)
GE   7.25 (-8.69%)
TSLA   504.79 (-3.67%)
AMD   46.20 (+1.58%)
T   28.13 (-3.50%)
ACB   0.85 (-6.59%)
F   4.54 (-6.00%)
NFLX   368.75 (-1.80%)
BAC   20.01 (-5.79%)
GILD   73.31 (-1.94%)
PRI   85.31 (-4.05%)
DIS   96.12 (-0.50%)
S&P 500   2,507.52 (-2.98%)
DOW   21,341.90 (-2.62%)
QQQ   186.19 (-2.22%)
AAPL   246.42 (-3.09%)
FB   161.92 (-2.93%)
MSFT   155.82 (-1.20%)
GOOGL   1,121.92 (-3.45%)
AMZN   1,929.24 (-1.05%)
CGC   14.11 (-2.49%)
NVDA   256.04 (-2.87%)
BABA   191.16 (-1.71%)
MU   41.44 (-1.47%)
GE   7.25 (-8.69%)
TSLA   504.79 (-3.67%)
AMD   46.20 (+1.58%)
T   28.13 (-3.50%)
ACB   0.85 (-6.59%)
F   4.54 (-6.00%)
NFLX   368.75 (-1.80%)
BAC   20.01 (-5.79%)
GILD   73.31 (-1.94%)
PRI   85.31 (-4.05%)
DIS   96.12 (-0.50%)
S&P 500   2,507.52 (-2.98%)
DOW   21,341.90 (-2.62%)
QQQ   186.19 (-2.22%)
AAPL   246.42 (-3.09%)
FB   161.92 (-2.93%)
MSFT   155.82 (-1.20%)
GOOGL   1,121.92 (-3.45%)
AMZN   1,929.24 (-1.05%)
CGC   14.11 (-2.49%)
NVDA   256.04 (-2.87%)
BABA   191.16 (-1.71%)
MU   41.44 (-1.47%)
GE   7.25 (-8.69%)
TSLA   504.79 (-3.67%)
AMD   46.20 (+1.58%)
T   28.13 (-3.50%)
ACB   0.85 (-6.59%)
F   4.54 (-6.00%)
NFLX   368.75 (-1.80%)
BAC   20.01 (-5.79%)
GILD   73.31 (-1.94%)
PRI   85.31 (-4.05%)
DIS   96.12 (-0.50%)
Log in

NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, Forecast & News

$18.78
+0.41 (+2.23 %)
(As of 04/1/2020 11:43 AM ET)
Today's Range
$17.66
Now: $18.78
$18.94
50-Day Range
$13.37
MA: $18.77
$22.25
52-Week Range
$10.70
Now: $18.78
$27.68
Volume15,278 shs
Average Volume835,405 shs
Market Capitalization$1.39 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.37
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise additional rare disease programs; a program for the treatment of hypercholesterolemia; and various programs in various therapeutic areas involving liver function. The company has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Read More
Dicerna Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DRNA
CUSIPN/A
Phone617-621-8097

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.90 million
Book Value$2.22 per share

Profitability

Net Income$-120,460,000.00
Net Margins-503.93%

Miscellaneous

Employees78
Market Cap$1.39 billion
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive DRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter.


Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

How has Dicerna Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DRNA stock has increased by 11.7% and is now trading at $18.86. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Dicerna Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dicerna Pharmaceuticals.

When is Dicerna Pharmaceuticals' next earnings date?

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Dicerna Pharmaceuticals.

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) announced its quarterly earnings data on Thursday, February, 27th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.50. The biopharmaceutical company had revenue of $7.08 million for the quarter, compared to analysts' expectations of $26.40 million. Dicerna Pharmaceuticals had a negative return on equity of 76.93% and a negative net margin of 503.93%. View Dicerna Pharmaceuticals' earnings history.

What price target have analysts set for DRNA?

10 equities research analysts have issued 12 month price targets for Dicerna Pharmaceuticals' stock. Their forecasts range from $18.00 to $50.00. On average, they expect Dicerna Pharmaceuticals' share price to reach $31.22 in the next year. This suggests a possible upside of 65.5% from the stock's current price. View analysts' price targets for Dicerna Pharmaceuticals.

Has Dicerna Pharmaceuticals been receiving favorable news coverage?

Media coverage about DRNA stock has been trending very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dicerna Pharmaceuticals earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutDicerna Pharmaceuticals.

Are investors shorting Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals saw a decrease in short interest during the month of February. As of February 28th, there was short interest totaling 3,060,000 shares, a decrease of 10.5% from the February 13th total of 3,420,000 shares. Based on an average daily trading volume, of 664,300 shares, the short-interest ratio is currently 4.6 days. Approximately 6.8% of the shares of the company are sold short. View Dicerna Pharmaceuticals' Current Options Chain.

Who are some of Dicerna Pharmaceuticals' key competitors?

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Arbutus Biopharma (ABUS), Amarin (AMRN), TG Therapeutics (TGTX), Sorrento Therapeutics (SRNE), Array Biopharma (ARRY), Crispr Therapeutics (CRSP), Exelixis (EXEL) and Gilead Sciences (GILD).

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the following people:
  • Dr. Douglas M. Fambrough III, Co-Founder, CEO, Pres & Director (Age 50)
  • Dr. Bob D. Brown, Chief Scientific Officer & Sr. VP (Age 54)
  • Dr. Ralf H. Rosskamp, Chief Medical Officer (Age 66)
  • Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory Board
  • Prof. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 72)

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

How do I buy shares of Dicerna Pharmaceuticals?

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $18.86.

How big of a company is Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals has a market capitalization of $1.39 billion and generates $23.90 million in revenue each year. The biopharmaceutical company earns $-120,460,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe. View additional information about Dicerna Pharmaceuticals.

What is Dicerna Pharmaceuticals' official website?

The official website for Dicerna Pharmaceuticals is http://www.dicerna.com/.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]


MarketBeat Community Rating for Dicerna Pharmaceuticals (NASDAQ DRNA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  415 (Vote Outperform)
Underperform Votes:  276 (Vote Underperform)
Total Votes:  691
MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe DRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel